GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Cyclically Adjusted PB Ratio

Vanda Pharmaceuticals (Vanda Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.76 (As of May. 26, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Vanda Pharmaceuticals's current share price is $5.23. Vanda Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $6.85. Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.76.

The historical rank and industry rank for Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

VNDA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.54   Med: 5.41   Max: 14.44
Current: 0.76

During the past years, Vanda Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 14.44. The lowest was 0.54. And the median was 5.41.

VNDA's Cyclically Adjusted PB Ratio is ranked better than
69.37% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs VNDA: 0.76

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $9.348. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.85 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.05 3.85 3.58 1.34 0.65

Vanda Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 1.08 0.68 0.65 0.60

Competitive Comparison of Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=5.23/6.85
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Vanda Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9.348/131.7762*131.7762
=9.348

Current CPI (Mar. 2024) = 131.7762.

Vanda Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.026 100.560 0.034
201409 0.031 100.428 0.041
201412 3.876 99.070 5.156
201503 3.648 99.621 4.825
201506 3.543 100.684 4.637
201509 3.409 100.392 4.475
201512 3.107 99.792 4.103
201603 2.853 100.470 3.742
201606 2.810 101.688 3.641
201609 2.940 101.861 3.803
201612 2.985 101.863 3.862
201703 2.877 102.862 3.686
201706 2.930 103.349 3.736
201709 2.904 104.136 3.675
201712 2.924 104.011 3.705
201803 4.628 105.290 5.792
201806 4.797 106.317 5.946
201809 4.989 106.507 6.173
201812 5.248 105.998 6.524
201903 5.257 107.251 6.459
201906 5.570 108.070 6.792
201909 7.517 108.329 9.144
201912 7.674 108.420 9.327
202003 7.692 108.902 9.308
202006 7.900 108.767 9.571
202009 8.056 109.815 9.667
202012 8.261 109.897 9.906
202103 8.417 111.754 9.925
202106 8.651 114.631 9.945
202109 8.855 115.734 10.082
202112 9.033 117.630 10.119
202203 8.889 121.301 9.657
202206 8.993 125.017 9.479
202209 9.112 125.227 9.589
202212 9.284 125.222 9.770
202303 9.327 127.348 9.651
202306 9.390 128.729 9.612
202309 9.440 129.860 9.579
202312 9.471 129.419 9.643
202403 9.348 131.776 9.348

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vanda Pharmaceuticals  (NAS:VNDA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Executives
Joakim Wijkstrom officer: SVP, Chief Marketing Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran officer: VP, Acting CFO & Treasurer C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams officer: SVP & General Counsel C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos director, officer: Chief Executive Officer 9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks officer: SVP, Business Development 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins director 1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones officer: Chief Corp. Affairs Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos director 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan director 20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly officer: SVP, CFO, Treasurer & Secretar C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi officer: SVP, General Manager Europe 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341